TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells

Oncogene

Volumn 34, Issue 16, 2014, Pages 2138-2144

  Tuthill, M H ^a,c   Montinaro, A ^a,d   Zinngrebe, J ^a,d   Prieske, K ^a,e   Draber, P ^a,d   Prieske, S ^a,e   Newsom Davis, T ^a,c   Von Karstedt, S ^a,d   Graves, J ^b   Walczak, H ^a,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b AMGEN INC   (United States)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CONATUMUMAB; FC RECEPTOR; FCGR1A PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN BINDING; PYRAZINE DERIVATIVE; RECOMBINANT PROTEIN; TNFRSF10B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; LIVER CELL; OVARIAN NEOPLASMS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; BORTEZOMIB; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; HEPATOCYTES; HUMANS; OVARIAN NEOPLASMS; PROTEIN BINDING; PYRAZINES; RECEPTORS, IGG; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS;

EID: 84939874775     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.156     Document Type: Article

References (29)

1. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
2. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
3. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385.
4. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006; 12: 2640-2646.
5. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28: 2839-2846.
6. Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis 2009; 14: 607-623.
7. Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 2010; 9: 618-631.
8. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 4442-4451.
9. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson Jr JJ, Rocha-Lima CM et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012; 23: 2834-2842.
10. Paz-Ares L, Balint B, de Boer RH, Van Meerbeeck JP, Wierzbicki R, De Souza P et al. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. J Thoracic Oncol 2013; 8: 329-337.
11. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13: 6187-6194.
12. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011; 19: 101-113.
13. Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hammerling GJ, Schwendener R et al. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol 2010; 185: 532-541.
14. Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN et al. The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol 2012; 227: 136-145.
15. Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M et al. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 2007; 12: 635-655.
16. Petrucci E, Pasquini L, Bernabei M, Saulle E, Biffoni M, Accarpio F et al. A small molecule SMAC mimic LBW242 potentiates TRAIL-and anticancer drug-mediated cell death of ovarian cancer cells. PLoS ONE 2012; 7: E35073.
17. Petrucci E, Pasquini L, Bernabei M, Saulle E, Biffoni M, Accarpio F et al. A small molecule SMAC mimic LBW242 potentiates TRAIL-and anticancer drug-mediated cell death of ovarian cancer cells. PLoS ONE 2012; 7: E35073.
18. Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12: 214-219.
19. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L et al. A first-inhuman study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010; 16: 5883-5891.
20. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol 2007; 39: 1462-1475.
21. Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piche A. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene Engl 2010; 29: 5523-5536.
22. Gillissen B, Richter A, Overkamp T, Essmann F, Hemmati PG, Preissner R et al. Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode. Cell Death Dis 2013; 4: E643.
23. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAILor anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-815.
24. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 2008; 68: 7956-7965.
25. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology (Baltimore, Md) 2005; 42: 588-597.
26. Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology (Baltimore, Md) 2007; 45: 649-658.
27. Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. Mol Cancer Ther 2013; 12: 2735-2747.
28. Lemke J, von Karstedt S, Abd El Hay M, Conti A, Arce F, Montinaro A et al. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Diff 2014; 21: 491-502.
29. Lecis D, Mastrangelo E, Belvisi L, Bolognesi M, Civera M, Cossu F et al. Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization. Bioorg Med Chem 2012; 20: 6709-6723.